Related by context. All words. (Click for frequent words.) 70 metastatic colorectal 69 prostate carcinomas 69 LHRH receptor positive 68 demonstrated antitumor activity 68 syngeneic 68 allogeneic bone marrow 68 lymphomas leukemias 68 metastatic gastric 68 pancreatic adenocarcinoma 68 chemoresistant 67 recurrent glioblastoma multiforme 67 stem cell engraftment 67 transplantation HCT 67 recurrent NSCLC 67 kidney urologic 67 papillary renal cell carcinoma 67 colorectal carcinoma 67 haematopoietic 67 ovarian carcinoma 67 ovarian breast 66 unresectable tumors 66 prostate carcinoma 66 allogeneic hematopoietic stem cell 66 pancreatic lung 66 undergoing hematopoietic stem 66 haematologic malignancies 66 pancreatic islet 66 allogeneic HSCT 66 biliary tract cancer 66 chemo resistant 66 malignant pleural mesothelioma 66 pediatric acute lymphoblastic 66 renal cell carcinomas 66 sarcomatoid 66 malignant ascites 65 Waldenstrom macroglobulinemia 65 cisplatin resistant 65 pulmonary metastases 65 pancreatic carcinoma 65 Surgical resection 65 Aplidin 65 carcinoma HCC 65 Glioblastoma Multiforme 65 Circulating tumor cells 65 pancreatic colon 65 CYT# potent vascular disrupting 65 p# biomarker 65 gastrointestinal stromal tumors 65 T1c 65 transplantation HSCT 65 nonsmall cell lung cancer 65 cervical lymph node 65 colorectal adenocarcinoma 65 benign neoplasms 65 metastatic malignant 65 haematopoietic stem cell 65 pancreatic ductal 65 metastatic bladder 65 bladder ovarian 65 AGTR1 65 Gleevec resistant 65 Temodar ® 65 adjuvant cisplatin 65 Acute myeloid leukemia 65 Li Fraumeni Syndrome 65 gastrointestinal stromal tumors GISTs 65 localized renal 65 autologous transplants 64 advanced pancreatic neuroendocrine 64 thymectomy 64 refractory colorectal cancer 64 breast carcinoma 64 leukemia multiple myeloma 64 refractory gastrointestinal stromal 64 histone deacetylase inhibitor 64 genitourinary cancers 64 autologous hematopoietic stem cell 64 allogeneic hematopoietic cell 64 Papillary 64 BrachySil TM 64 Endometrial 64 underwent surgical resection 64 GRNOPC1 contains 64 Hodgkin lymphoma HL 64 Mesenchymal 64 bladder tumors 64 hematopoietic cell 64 metastatic neuroendocrine tumors 64 nonmetastatic 64 membranous nephropathy 64 malignant pancreatic 64 relapsed MM 64 pretransplant 64 autosomal dominant polycystic kidney 64 carcinoid 64 metastatic liver 64 autologous transplantation 64 urothelial carcinoma 64 leukemia AML 64 acute myeloid 64 anti angiogenic therapy 64 chronic thromboembolic pulmonary 64 ductal carcinomas 63 dyskeratosis congenita 63 multiple myeloma MM 63 antiproliferative effects 63 hematological diseases 63 HER2 positive cancers 63 gastrointestinal stromal tumors GIST 63 novel VDA molecule 63 pT2 63 myelodysplastic myeloproliferative diseases 63 oligodendrogliomas 63 YONDELIS 63 Cholangiocarcinoma 63 hepatobiliary 63 KRAS mutated 63 pancreatic endocrine 63 squamous cell lung cancer 63 nodal metastasis 63 sunitinib Sutent 63 Vandetanib 63 lymphoid malignancies 63 pancreatic prostate 63 gefitinib Iressa 63 ductal adenocarcinoma 63 Leukemias 63 hypereosinophilic syndrome 63 colorectal gastric 63 mutated K ras 63 Virulizin ® 63 bile duct cancers 63 untreated metastatic melanoma 63 renal carcinoma 63 HuCNS SC ® 63 mesangial 63 differentiated thyroid 63 Acute myeloid leukemia AML 63 brivanib 63 tumors GIST 63 castrate resistant 63 concurrent chemoradiation 63 abnormal p# 63 breast pancreatic 63 mTOR mammalian target 63 Allogeneic 63 metastatic pancreatic 63 KRAS mutant 63 Squamous 63 urothelial cancer 63 Daclizumab 63 cisplatin gemcitabine 63 sorafenib Nexavar 63 neoadjuvant therapy 63 neuroendocrine cancers 63 polycythemia vera PV 63 pancreatic neuroendocrine tumors 63 deCODE ProstateCancer TM 63 metastatic GIST 63 adipose derived regenerative 63 metaplasia 63 refractory acute myeloid 63 BCG refractory 63 allogeneic stem cell 63 Chronic lymphocytic leukemia 63 Factor Receptor 63 relapsed leukemia 63 VEGF induced 63 cervical lymph nodes 63 pheochromocytoma 63 NSCLC tumors 63 Hepatocellular Carcinoma HCC 63 Kit CD# positive 63 MGd 62 Everolimus 62 Enzastaurin 62 potent antiproliferative 62 solid organ transplantation 62 Pancreatic 62 OvaRex MAb 62 myelofibrosis polycythemia vera 62 myeloablative 62 resistant hormone refractory 62 tumorigenicity 62 recurrent metastatic 62 CCR9 62 renal tumors 62 PARP inhibition 62 Islet cell 62 BRCA deficient 62 neoplastic 62 cancer mCRC 62 anti angiogenic agents 62 skeletal metastases 62 Anaplastic 62 Phase 1b clinical trials 62 BRAF mutated 62 Squamous cell 62 Belldegrun 62 accumulate preferentially 62 Myelodysplastic syndromes MDS 62 liver metastasis 62 Sezary syndrome 62 Aflibercept 62 castrate resistant prostate cancer 62 medically inoperable 62 AA amyloidosis 62 primary hyperparathyroidism 62 gastric adenocarcinoma 62 K ras mutations 62 MAGE A3 ASCI 62 mucinous 62 refractory Hodgkin 62 endocrine therapies 62 complement inhibitor eculizumab 62 surgically resectable 62 Myelodysplastic Syndrome 62 ixabepilone 62 stem cell transplantations 62 smoldering myeloma 62 pro angiogenic 62 adult mesenchymal stem 62 depsipeptide 62 recurrent glioblastoma 62 adrenocortical cancer 62 Lymph node 62 extramedullary 62 GRNCM1 62 #beta HSD1 62 cholangiocarcinoma 62 esophageal gastric 62 Ataluren 62 underwent resection 62 fibrosarcoma 62 chronic idiopathic thrombocytopenic purpura 62 Ph + acute lymphoblastic 62 RRM1 62 polycythemia vera essential thrombocythemia 62 radiotherapeutic 62 malignant transformation 62 somatostatin receptors 62 paclitaxel poliglumex 62 cervical carcinoma 62 HIF 1α 62 ZACTIMA 62 cytoreduction 62 farletuzumab 62 metachronous 62 Antitumor Activity 62 tuberous sclerosis TS 62 breast carcinomas 62 cytoreductive nephrectomy 62 Hematopoietic 62 EGFR mutation positive 62 cervical prostate 62 targeted radiotherapeutic 62 ovarian colon 62 angiogenesis inhibitor 62 pelvic lymphadenectomy 62 Renal Cell Carcinoma RCC 62 receptor tyrosine kinase inhibitor 62 K ras 62 telomerase therapeutic 62 T1a 62 Adenomas 62 BR.# 62 antiangiogenic therapy 62 pain palliation 62 Antisoma AS# 62 vinca alkaloid 62 thyroid carcinoma 61 Prognostic factors 61 antibody MAb 61 HER2 positive breast 61 operable breast cancer 61 Glioblastoma Multiforme GBM 61 FGFR3 61 circulating endothelial cells 61 Xelox 61 chronic myeloid 61 thalidomide Thalomid 61 CTEPH 61 advanced medullary thyroid 61 Azacitidine 61 ErbB2 positive 61 Madin Darby canine 61 Basal cell 61 thymic carcinoma 61 humanised monoclonal antibody 61 castration resistant 61 immuno modulatory 61 antisense inhibitors 61 poly ADP ribose polymerase 61 SIR Spheres 61 Neulasta ® 61 NSABP 61 neuroendocrine tumors 61 resected tumors 61 intratumoral injection 61 Familial Adenomatous Polyposis 61 IgG1 monoclonal antibody 61 bladder prostate 61 RECIST Response Evaluation Criteria 61 Phase #b/#a clinical 61 adjuvant radiotherapy 61 Inhaled nitric oxide 61 ovarian pancreatic 61 epithelial ovarian 61 ovarian prostate 61 neovascularization 61 malignant lymphomas 61 metastatic ovarian cancer 61 NPHP 61 Interferon beta 61 murine model 61 LHON 61 engineered bladders 61 renal transplants 61 renal fibrosis 61 cell transplantation 61 refractory chronic lymphocytic 61 Hedgehog Pathway Inhibitor 61 surgically resected 61 precancerous condition 61 Epidermal Growth Factor Receptor 61 microsphere therapy 61 allogenic stem cell 61 biliary tract 61 Bezielle 61 vestibular schwannomas 61 pancreatic ductal adenocarcinoma 61 ADPKD 61 hematopoietic malignancies 61 vasculopathy 61 basal cell skin 61 unresectable liver cancer 61 MGMT gene 61 Pancreas Cancer 61 arteriovenous malformations 61 taxane refractory 61 refractory metastatic 61 lung esophageal 61 chronic eosinophilic leukemia 61 untreated metastatic pancreatic 61 HER2 positivity 61 ovarian lung 61 Omacetaxine 61 STRIDE PD 61 biotherapy 61 Cloretazine R 61 esophagogastric junction 61 Phase #/#a trial 61 allogenic 61 ANCA associated 61 thymoma 61 colon carcinoma 61 HDL Selective Delipidation 61 ocular disorders 61 Advanced Renal Cell 61 Amrubicin 61 dasatinib Sprycel 61 KRAS mutation 61 mouse xenograft models 61 neoadjuvant setting 61 MALT lymphoma 61 Progenitor Cells 61 CEQ# 61 colorectal lung 61 haematological cancers 61 recurrent ovarian 61 CTAP# Capsules 61 androgen dependent 61 anti CD3 antibody 61 uterine tumors 61 follicular Non Hodgkin 61 leukemia lymphoma multiple myeloma 61 Atypical Hemolytic Uremic Syndrome 61 antiangiogenic agent 61 IMC #B 61 cells hESCs 61 Temsirolimus 61 esophagus bladder 61 transthyretin amyloidosis 61 TRAIL induced apoptosis 61 anti fibrotic 61 substantially excreted 61 SNT MC# 61 benign prostatic hyperplasia enlarged 61 MELAS 61 subependymal giant cell 61 adhesion molecule EpCAM expressing 61 cutaneous T 61 metastatic adenocarcinoma 61 chimeric monoclonal antibody 61 radiolabeled TM# 61 Ceflatonin 61 allogeneic transplants 61 targeted nucleotide prodrug 61 TRO# 61 mTOR inhibitors 61 Carcinoid tumors 61 chemoradiation therapy 61 orthotopic 61 Stereotactic Body Radiation Therapy 61 Malignant Melanoma 61 Prednisone Against Refractory 61 squamous cell carcinoma SCC 61 hepatorenal syndrome 61 ELACYT 61 Evoltra ® 61 occlusive disease 61 TACI Ig 61 BRAF V#E mutation 61 breast cancer metastasis 61 essential thrombocythemia ET 61 ADAMTS# 61 Peripheral Blood 61 placental derived 61 lymphangiogenesis 61 Wilms tumors 61 systemic anaplastic large 61 PNET 61 paroxysmal nocturnal hemoglobinuria 61 Mitomycin C 61 Genasense ® 61 fallopian tube carcinoma 61 Sipuleucel T 61 localized prostate 61 GRN# 61 R sorafenib tablets 61 peritoneal carcinomatosis 61 malignant lymphoma 61 prostate adenocarcinoma 61 Ribavirin causes 61 Canvaxin TM 61 testicular germ cell 61 Torisel temsirolimus 61 IGF IR 61 leukemia lymphomas 61 engineered RAP peptides 60 hematologic disorders 60 sCD# 60 acinar 60 relapsing remitting MS RRMS 60 leukemia myeloma 60 Neupogen ® 60 Anthracycline 60 pituitary adenomas 60 Immunohistochemical analysis 60 pancreatic transplantation 60 leiomyomas 60 TTR amyloidosis 60 Autologous stem cell 60 Squalamine 60 xenograft models 60 bladder carcinoma 60 hyperplastic 60 flavopiridol 60 histologically proven 60 Squamous Cell Carcinoma 60 TTF Therapy 60 CD# + [001] 60 Tanespimycin 60 fosbretabulin 60 GISTs 60 recombinant erythropoietin 60 idiopathic thrombocytopenic purpura 60 ADVEXIN therapy 60 Castration Resistant Prostate Cancer 60 GVAX ® 60 steroid refractory 60 cardio renal 60 Adjuvant chemotherapy 60 stage IIIb IV 60 Fibroblast 60 Basal Cell 60 null responder 60 parathyroid carcinoma 60 mismatched bone marrow 60 thromboembolic disease 60 premalignant 60 DCVax R 60 EGFR HER2 60 myeloproliferative disorders 60 oral picoplatin 60 malignant ovarian 60 epithelioid 60 radiation sensitizer 60 adenomatous 60 GORE TAG Device 60 acadesine 60 cilengitide 60 cells overexpressing 60 Nexavar sorafenib 60 EGFR mutant 60 AA Amyloidosis 60 papillary carcinoma 60 Estrogen Receptor 60 Bayer Nexavar 60 osteosarcomas 60 Hepatocellular 60 lung liver pancreas 60 5 fluorouracil leucovorin 60 chronic granulomatous disease 60 Islet transplantation 60 myeloproliferative neoplasms MPNs 60 tumoral 60 testicular cancers 60 Alessandro Riva 60 breast endometrial 60 Bayer HealthCare Onyx Pharmaceuticals 60 DCVax 60 Leydig cell 60 MAGE A3 60 R lenalidomide 60 IL# PE#QQR 60 Eosinophils 60 haematological malignancies 60 transplant HSCT 60 Xenograft 60 xenograft 60 PEG SN# 60 thrombocytopenic 60 chemosensitizer 60 PrevOnco 60 Adaptive Radiation Therapy 60 Doxil ® 60 percutaneous cryoablation 60 Renal Cell Carcinoma 60 pulmonary metastasis 60 non mutated KRAS 60 transarterial 60 kidney liver pancreas 60 autologous SCT 60 antiangiogenic drugs 60 Lung transplantation 60 HNSCC 60 Hurthle cell 60 potently inhibit 60 NeoLipid R 60 pathologic diagnosis 60 fallopian tube cancers 60 insulin secreting beta 60 PhG alpha 1 60 neoadjuvant treatment 60 targeted antifolate 60 KRAS oncogene 60 Glioma 60 nasopharyngeal carcinoma 60 immunoregulation 60 Fibrillex TM 60 chemopreventive agent 60 EGFR receptor 60 mda 7 60 debulking surgery 60 Exherin TM 60 immune modulating 60 adipogenic 60 antiangiogenesis 60 gastrointestinal stromal tumor GIST 60 Intra arterial 60 stage IIIB 60 HER2 overexpression 60 Histologically 60 basal cell carcinoma BCC 60 oral squamous cell 60 Chronic Lymphocytic Leukemia 60 IDH1 mutation 60 gastric pancreatic 60 Trastuzumab 60 Lymphoid 60 PSMA ADC 60 bronchoalveolar lavage fluid 60 R roscovitine 60 gastro intestinal inflammation 60 lung fibrosis 60 p# MAP kinase inhibitor 60 HBeAg negative 60 CLL SLL 60 Immunotherapeutic 60 EGFR blockers 60 cytotoxic therapies 60 Meningiomas 60 Predict Response 60 Philadelphia Chromosome Positive 60 metastatic RCC 60 Cell Transplant 60 recurrent glioma 60 Acute Myelogenous Leukemia 60 neurotrophic 60 Janus kinase 60 nonhuman primate model 60 Hematopoietic stem cell 60 AML acute myeloid 60 Myelodysplastic syndrome 60 cellular immunotherapy 60 PKCi 60 vaccine GRNVAC1 60 proliferative disorders 60 Adult Stem Cell Therapy 60 KRAS wild 60 recurrent glioblastoma multiforme GBM 60 lenalidomide Revlimid R 60 lymphoid organs 60 oral clodronate 60 imatinib Gleevec 60 metastatic renal cell carcinoma 60 TET2 60 Hepatocellular Carcinoma 60 gastrointestinal stromal tumor 60 angiogenesis inhibition 60 Selective Internal 60 OHR/AVR# 60 riociguat 60 Golimumab 60 temozolomide Temodar 60 CMV infections 60 VEGF expression 60 pelvic malignancies 60 noninvasive outpatient 60 anastrazole 60 Combination REOLYSIN R 60 bevacizumab Avastin ® 60 stage IIIA 60 metastatic lymph nodes 60 pancreatic NET 60 primitive neuroectodermal tumor 60 Multiple Myeloma MM 60 ccRCC 60 completely resected 60 stage IIIB IV 60 Li Fraumeni 60 Aurora Kinase 60 Stromal 60 choroidal melanoma 60 uPA 60 CanAg 60 BRAF V#E 60 thoracoscopic lobectomy 60 malignant prostate 60 lung carcinomas 60 vaso occlusive crisis 60 Bucindolol 60 selective modulator 60 tumor infiltrating lymphocytes 60 insulin secreting 60 Mesenchymal Stem Cells 60 hepatic metastases 60 leukemias lymphomas 60 microsatellite instability 60 clonogenic 60 Mohs micrographic surgery 60 proteasome inhibitor 60 malignant cancerous 60 ZACTIMA TM ZD# 60 erlotinib Tarceva 60 grade cervical intraepithelial 60 preclinical efficacy 60 commercialize deforolimus 60 inducible nitric oxide synthase 60 RhuDex R 60 Follicular Lymphoma 60 tissue fibrosis 60 Vascugel ® 60 relapsed ovarian cancer 60 Cutaneous T 60 submandibular gland 60 Hypertrophy 60 CMV disease 60 ImmuKnow 60 Relapsed Refractory 60 Myelodysplasia 60 Monoclonal antibody 60 axitinib 60 EGFR expressing 60 transgenic rats 60 adipose derived stem cells 59 Metastatic 59 bronchoalveolar lavage BAL 59 alvespimycin 59 fibrin deposition 59 prostate bladder 59 plasmacytoid 59 adult chronic ITP 59 lung metastasis 59 hepatoma 59 trastuzumab Herceptin ® 59 neovascular diseases 59 laparoscopic radical nephrectomy 59 removed laparoscopically 59 intravesical infusion therapy 59 tramiprosate Alzhemed TM 59 humanised antibody 59 clinicopathological 59 preoperative chemotherapy 59 prostate cancer CaP 59 prostate cancer mCRPC 59 neural progenitor 59 hypervascular tumors 59 cell carcinoma RCC 59 histologies 59 potent inducer 59 AFRS TM 59 Epstein Barr Virus EBV 59 Intravenous CP 59 aurora kinase 59 lung pancreatic 59 Her2 positive 59 gastric carcinoma 59 investigational monoclonal antibody 59 Squamous Cell 59 SUTENT ® 59 haematologic 59 metastatic malignant melanoma 59 Cell Lymphoma 59 minimally symptomatic 59 OncoVex 59 Vidaza azacitidine 59 HER2 receptor 59 metastatic basal cell 59 von Hippel Lindau 59 hepatocellular carcinoma liver 59 Transcatheter 59 hepatocellular carcinoma HCC 59 neoplastic cells 59 underwent liver transplantation 59 Neoadjuvant 59 situ LCIS 59 non resectable metastatic 59 histone deacetylase HDAC inhibitor 59 Vicinium TM 59 docetaxel Taxotere ® 59 radical retropubic prostatectomy 59 ReN# 59 cediranib 59 orally administered inhibitor 59 myeloproliferative diseases 59 myeloproliferative neoplasms 59 MPGN 59 antiretroviral naïve 59 renal transplantation 59 LungAlert TM 59 cisplatin chemotherapy 59 locoregional recurrence 59 Tr DNA 59 diseases fat malabsorption 59 PAOD 59 FLT3 59 mutated KRAS 59 lymphocytic leukemia 59 ovarian endometrial 59 neoplastic diseases 59 Immunohistochemical staining 59 Acute myelogenous leukemia 59 lymphoid cells 59 Velcade bortezomib 59 neuroendocrine carcinoma 59 sunitinib malate 59 Archexin 59 colorectal liver metastases 59 myelofibrosis MF 59 radioimmunotherapy RIT 59 small lymphocytic lymphoma 59 secretes insulin 59 acetonide FA 59 bronchogenic carcinoma 59 hepatocellular carcinoma 59 carcinoid tumors 59 hormone refractory 59 systemic amyloidosis 59 Myelodysplastic Syndrome MDS 59 BCIRG 59 prostate ovarian 59 Anti VEGF 59 immunohistochemical 59 StemEx R 59 Metastatic breast cancer 59 BRAF inhibitor 59 kidney fibrosis 59 leukemia ALL 59 cervical breast 59 Hormone Refractory Prostate Cancer 59 LRP5 59 stage IIIb 59 microangiopathy 59 multisystem disease 59 neovascularisation 59 heavily pretreated 59 FUSILEV enhances 59 transdifferentiation 59 pancreas colon 59 immunohistochemical staining 59 peripheral vasculature 59 colon esophageal 59 interstitial brachytherapy 59 LEUKINE 59 atypical hemolytic uremic syndrome 59 biliary tree 59 Xanafide 59 HuMax 59 ENMD # 59 lymphoproliferative disorders 59 homozygous FH 59 Pertuzumab 59 cytomegalovirus CMV 59 choroidal neovascularization 59 tubulin inhibitor 59 histologically confirmed 59 immunosuppressive regimen 59 renoprotective 59 intraductal 59 GW# [003] 59 medullary thyroid cancer 59 Troxatyl 59 Langerhans cell histiocytosis 59 cat dander allergy 59 alpha fetoprotein AFP 59 myelomas 59 hormonally sensitive 59 bone metastasis 59 lymphoproliferative diseases 59 intracranial tumors 59 Muraglitazar 59 Eculizumab 59 motor neuron degeneration 59 intravesical therapy 59 targeting CD# 59 demethylating agents 59 Neo Bladder Augment 59 myeloproliferative disorder 59 advanced hepatocellular carcinoma 59 BRAF gene mutations 59 Tyrosine Kinase Inhibitor 59 atypical rhabdoid tumor 59 Idiopathic Pulmonary Fibrosis 59 invasive ductal 59 pancreatic neuroendocrine 59 retinoic acid receptor 59 colorectum 59 taxane chemotherapy 59 immunocompetent 59 Solazed 59 cyclophilin inhibitors 59 myeloid metaplasia 59 urothelial 59 multiorgan 59 OMP #R# 59 Annamycin 59 JAK3 59 antibody mediated 59 Panzem 59 parathyroid 59 metastatic castration resistant 59 cMET 59 elacytarabine 59 intestinal polyps 59 laparoscopic nephrectomy 59 KRAS mutations 59 histological subtype 59 mutated p# 59 Hydroxyurea 59 liver resection 59 noninvasive painless 59 Progenitor cells 59 vitro pharmacology 59 epithelial tumors 59 intrahepatic bile duct 59 Fabry Disease 59 SHPT 59 interleukin IL -# 59 anti CD3 59 novel immunotherapies 59 IFN alpha 2a 59 androgen receptor AR 59 malignant neoplasm 59 Vascugel 59 vivo validation 59 murine models 59 PROSTVAC VF 59 relapsed multiple myeloma 59 invasive carcinoma 59 NMIBC 59 spontaneous regression 59 Accelerated Partial Breast Irradiation 59 HER2 positive metastatic breast 59 Colon polyps 59 mouse neural stem 59 Introgen ADVEXIN 59 Chronic Lymphocytic Leukemia CLL 59 allogeneic SCT 59 fibroma 59 advanced epithelial ovarian 59 transthyretin TTR mediated amyloidosis 59 activin 59 vascular disrupting agents 59 plerixafor 59 INSPIRE Trial Phase III 59 dose melphalan 59 mediated inhibition 59 colorectal ovarian 59 Campath alemtuzumab 59 Medullary thyroid cancer 59 radioiodine therapy 59 receptor inhibitor 59 polycystic kidneys 59 hepatocellular cancer 59 Zybrestat 59 embryonal 59 Endothelial 59 paclitaxel Taxol R 59 biliary cancer 59 idiopathic myelofibrosis 59 cyclin dependent kinase inhibitor 59 immunosuppression therapy 59 Carcinoma 59 imatinib resistance 59 subconjunctival injection 59 diagnostic biomarker 59 hedgehog signaling pathway 59 precursor lesions 59 Prolongs Survival 59 experimental autoimmune encephalomyelitis 59 TNFerade TM 59 SNT-MC#/idebenone 59 dilated cardiomyopathy DCM 59 drug belatacept 59 antimitotic 59 relapsed mantle 59 radiosensitivity 59 immunotherapy treatments 59 extranodal 59 atypical Hemolytic Uremic Syndrome 59 micrometastasis 59 Liver transplantation 59 colorectal cancer liver metastases 59 rALLy clinical trial 59 anticancer therapy 59 Trofex 59 antitumor effect 59 GATA3 59 SOD2 gene 59 advanced metastatic renal 59 aMCI precursor 59 fibrocytes 59 uricase 59 M2 subunit 59 extracranial 59 transgenic mouse models 59 cytological 59 SSc 59 Symadex 59 refractory ovarian cancer 59 Chronic myeloid leukemia CML 59 Azedra 59 trabectedin 59 Adjuvant Chemotherapy 59 azacytidine 59 metastatic bone 59 Metastatic colorectal cancer 59 Tissue Factor 59 Waldenstrom Macroglobulinemia 59 autologous bone marrow 59 ipsilateral breast 59 basiliximab 59 Pemetrexed 59 CT Angiography 59 metastatic lesions 59 pathologic examination 59 Onconase 59 TTR gene 59 YONDELIS R 59 infantile NCL 59 chemotherapy cisplatin 59 TÎ ² 4 59 chemoradiotherapy 59 delipidation 59 cytokines IL 59 multikinase inhibitor 59 leukocyte adhesion 59 Diffuse Large B 59 hepatocellular carcinomas 59 cell carcinomas 59 Litx 58 hyperphenylalaninemia HPA due 58 PARP inhibitor 58 Neurofibromatosis type 58 achieved CCyR 58 hA# 58 primary immunodeficiencies 58 Systemic Sclerosis 58 grade squamous intraepithelial 58 Myelofibrosis 58 immunohistochemical analysis 58 endothelial activation 58 undergoing radical cystectomy 58 Cardiotoxicity 58 Allovectin 7 ® 58 B Cell Lymphoma 58 ASCO GU